Patient and transplant characteristics
| Variables . | Median (range) or n (%) . |
|---|---|
| Age at HSCT, y | 14.5 (4-24) |
| Sex | |
| Female | 13 (36.1) |
| Male | 23 (63.9) |
| Lymphoma subtypes | |
| ALCL | 14 (38.9) |
| DLBCL | 8 (22.2) |
| LL | 9 (25.0) |
| Other lymphomas | 5 (13.9) |
| Time to relapse after initial diagnosis, mo | |
| ≤12 | 12 (44.4) |
| >12 | 15 (55.6) |
| Disease status at HSCT | |
| CR | 15 (42.9) |
| PR | 17 (48.6) |
| SD | 3 (8.6) |
| Conditioning | |
| MAC | 27 (75.0) |
| RIC | 9 (25.0) |
| TBI | |
| TBI | 32 (88.9) |
| Non-TBI | 4 (11.1) |
| GVHD prophylaxis | |
| CD34+ selection | 4 (11.1) |
| CNI | 8 (22.2) |
| CNI/MTX | 21 (58.3) |
| Other | 3 (8.3) |
| Cell source | |
| Bone marrow | 26 (72.2) |
| PBSCT | 10 (27.8) |
| Donor type | |
| MRD | 13 (36.1) |
| MUD | 10 (27.8) |
| MMUD | 9 (25.0) |
| Haploidentical | 4 (11.1) |
| Variables . | Median (range) or n (%) . |
|---|---|
| Age at HSCT, y | 14.5 (4-24) |
| Sex | |
| Female | 13 (36.1) |
| Male | 23 (63.9) |
| Lymphoma subtypes | |
| ALCL | 14 (38.9) |
| DLBCL | 8 (22.2) |
| LL | 9 (25.0) |
| Other lymphomas | 5 (13.9) |
| Time to relapse after initial diagnosis, mo | |
| ≤12 | 12 (44.4) |
| >12 | 15 (55.6) |
| Disease status at HSCT | |
| CR | 15 (42.9) |
| PR | 17 (48.6) |
| SD | 3 (8.6) |
| Conditioning | |
| MAC | 27 (75.0) |
| RIC | 9 (25.0) |
| TBI | |
| TBI | 32 (88.9) |
| Non-TBI | 4 (11.1) |
| GVHD prophylaxis | |
| CD34+ selection | 4 (11.1) |
| CNI | 8 (22.2) |
| CNI/MTX | 21 (58.3) |
| Other | 3 (8.3) |
| Cell source | |
| Bone marrow | 26 (72.2) |
| PBSCT | 10 (27.8) |
| Donor type | |
| MRD | 13 (36.1) |
| MUD | 10 (27.8) |
| MMUD | 9 (25.0) |
| Haploidentical | 4 (11.1) |
CNI, calcineurin inhibitor; MAC, myeloablative conditioning; MMUD, mismatched unrelated donor; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; PBSCT, peripheral blood stem cell transplant; RIC, reduced-intensity conditioning; TBI, total-body irradiation.